Morgan Stanley
BBNX

Morgan Stanley’s Beta Bionics BBNX Stock Holding History

Morgan Stanley’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.4M Buy
4,227,634
+768,181
+22% +$11.4M ﹤0.01% 2278
2025
Q4 		$105M Sell
3,459,453
-302,130
-8% -$8.07M 0.01% 1408
2025
Q3 		$74.7M Buy
3,761,583
+812,218
+28% +$14.3M ﹤0.01% 1671
2025
Q2 		$42.9M Buy
2,949,365
+1,547,712
+110% +$21.9M ﹤0.01% 2065
2025
Q1 		$17.2M Buy
+1,401,653
New +$26.1M ﹤0.01% 2850

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Morgan Stanley's BBNX Position: Q1 2026 in Review

Morgan Stanley increased its Beta Bionics (BBNX) stake by 22% in Q1 2026, buying an estimated $11.4M and bringing the position to 4,227,634 shares worth $42.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2278.

Morgan Stanley first reported a position in BBNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $105M in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Morgan Stanley held 4,227,634 shares of Beta Bionics worth $42.4M as of Q1 2026.
  • Morgan Stanley bought 768,181 Beta Bionics shares in Q1 2026, an estimated $11.4M.
  • Beta Bionics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #2278 holding.
  • Morgan Stanley first reported a position in Beta Bionics in Q1 2025 and has held it in 5 quarters since.
  • Morgan Stanley's Beta Bionics position peaked at $105M in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.